EUVIMEDEUVIMED entdecken
QuerschnittstudieOpen Access · CC BY 4.0

Ocular comorbidities are common in multiple myeloma: results of a large cross-sectional survey

Rahul Banerjee iD, Jay Hydren, Jorge Arturo Hurtado Martínez, Mason Barnes, Patricia Alejandra Flores Pérez, Jennifer M Ahlstrom, Kara I Cicero, Gurbakhash Kaur, Parisa Taravati, Andrew J Cowan

The Oncologist · 14.11.2026

DOI: 10.1093/oncolo/oyag458 ↗

Kurz gefasst

Querschnittstudie in der Zeitschrift The Oncologist, online erschienen am 14.11.2026. Verfasst von Rahul Banerjee und 9 weiteren Autor:innen. Beteiligte Einrichtung: Fred Hutchinson Cancer Center, Seattle, WA, USA. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Both advancing age and multiple myeloma (MM) therapies such as belantamab mafodotin or dexamethasone can be risk factors for ocular complications. We conducted an international online survey of 508 patients with MM; 3% and 2% reported previous craniofacial radiation therapy or belantamab mafodotin, respectively. Common ocular comorbidities included cataracts (59%), dry eyes requiring eyedrops (37%), and blepharitis or styes (24%). Higher typical dexamethasone doses (≥20 milligrams weekly) were associated with cataracts after adjusting for advancing age and time since diagnosis. Compared to lower-dose dexamethasone (0-19 milligrams weekly), high-dose dexamethasone shifted the incidence curve of predicted cataracts approximately 5.4 years earlier. Although 82% of patients reported periodic eye exams (in line with ophthalmologic recommendations for older adults), only 31% had ever received such guidance from their MM teams. In conclusion, ocular issues are common in MM. Corticosteroid-sparing regimens may warrant attention across the age spectrum to reduce the risk of cataracts.

Schlagwörter

Stichwörter der Autor:innen

Multiple myelomabelantamab mafodotinblepharitiscataractseye healthglaucoma

Autor:innen und Institutionen

  • Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • University of Washington, Seattle, WA, USA.
  • HealthTree Foundation, Lehi, UT, USA.
  • Mount Sinai School of Medicine, New York, NY, USA.
  • BC Cancer Agency, Vancouver, BC, Canada.

ORCID-Profile: Rahul Banerjee

Zitieren

APA

Banerjee, R., Hydren, J., Hurtado Martínez, J. A., Barnes, M., Flores Pérez, P. A., Ahlstrom, J. M., Cicero, K. I., Kaur, G., Taravati, P., & Cowan, A. J. (2026). Ocular comorbidities are common in multiple myeloma: results of a large cross-sectional survey. The Oncologist. https://doi.org/10.1093/oncolo/oyag458

Vancouver

Banerjee R, Hydren J, Hurtado Martínez JA, Barnes M, Flores Pérez PA, Ahlstrom JM, et al. Ocular comorbidities are common in multiple myeloma: results of a large cross-sectional survey. The Oncologist. 2026. doi:10.1093/oncolo/oyag458

BibTeX
@article{Banerjee2026,
  author = {Banerjee, Rahul and Hydren, Jay and Hurtado Martínez, Jorge Arturo and Barnes, Mason and Flores Pérez, Patricia Alejandra and Ahlstrom, Jennifer M and Cicero, Kara I and Kaur, Gurbakhash and Taravati, Parisa and Cowan, Andrew J},
  title = {Ocular comorbidities are common in multiple myeloma: results of a large cross-sectional survey},
  journal = {The Oncologist},
  year = {2026},
  doi = {10.1093/oncolo/oyag458}
}
Kostenlos starten →